3646 results for «594»
3646 results
EuroPCR 2026 Closing Ceremony
22 May 2026 – From EuroPCR 2026
The EuroPCR 2026 Closing Ceremony marks the conclusion of this premier cardiology event, celebrating the latest advances and achievements in interventional cardiology. It offers an opportunity to reflect on the educational sessions, network with peers, and recognize outstanding contributions to the field.
Welcome to EuroPCR 2026
19 May 2026 – From EuroPCR 2026
Welcome to EuroPCR 2026, the premier event for interventional cardiology professionals. This edition offers cutting-edge scientific presentations, live cases, and interactive sessions designed to advance knowledge and clinical practice in cardiovascular interventions.
Addressing difficult anatomy in STEMI patients
21 May 2026 – From EuroPCR 2026
This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.
Pharmacology without borders, from coronary artherostenosis to radial artery
21 May 2026 – From EuroPCR 2026
This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Author
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.
Author
